<span item_type="fundamental" item_id="3aeb42a02c9d22472090052b90eaef21" counter_id="ST/US/ITRM" env="prod"></span><span item_type="announcement" item_id="582663282466619521" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 390 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.2, missing the estimate of USD -0.09.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -8.406 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Net product revenues for the third quarter of 2025 were $0.4 million, related to sales of ORLYNVAH™, which launched in August 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the third quarter of 2025 was - $9.0 million compared to a net loss of - $6.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li><li>Non-GAAP net loss for the third quarter of 2025 was - $7.3 million compared to a non-GAAP net loss of - $4.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li><li>Research and development expenses for the third quarter of 2025 were - $1.3 million, a decrease from - $3.1 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li><li>Selling, general, and administrative expenses for the third quarter of 2025 were - $6.5 million, an increase from - $1.8 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash and cash equivalents were $11.0 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Cost of sales expense for the third quarter of 2025 was - $0.02 million, primarily consisting of royalty payments to Pfizer Inc.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li><li>Amortization of intangible asset for the third quarter of 2025 was - $0.3 million, related to a regulatory milestone payment to Pfizer.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Iterum expects net product sales of ORLYNVAH™ to range between $5 million and $15 million in 2026, depending on uptake and payer coverage.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li><li>The company anticipates that its cash and cash equivalents, along with net proceeds from its at-the-market offering program, will be sufficient to fund operations into the second quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-ex99_1.htm"></span></li></ul>

Iterum Therap | 8-K: FY2025 Q3 Revenue: USD 390 K